01:05 PM EDT, 08/13/2025 (MT Newswires) -- CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows:

Following the fast rally we saw in ALNY shares after the solid Q2 results, we raise our target price to $500 from $443 based on our net present value (NPV) analysis. We maintain our 2025 EPS estimate at $0.87. We increase our 2026 EPS view to $3.76 from $3.23. Alnylam is a global commercial-stage biopharmaceutical company developing novel therapeutics based on RNA interference. We think Alnylam's focus on innovation, evidenced by its robust pipeline in the industry combined with its solid commercial execution, differentiates it from its biotech peers. We expect the strong momentum seen in Q2 to continue through 2025 and think the company can achieve bottom-line profitability this year, supported by solid improvements in top-line revenue and margins. We expect top-line revenue to reach $3.5 billion in 2025, up a robust 56% Y/Y after rising by 23% Y/Y in 2024.